Thermo Fisher Scientific Inc.

- The company’s guidance includes approximately $660 million of net interest expense for the year, which now includes financing for the Clario acquisition. - No mention of new or planned fundraising through equity in this earnings call excerpt. - The firm continues disciplined capital deployment via strategic M&A (e.g., acquisition of Clario and filtration/separation business from Solventum) and returning capital to shareholders (completed $3 billion share buybacks in January and plans approximately $700 million in dividends for the year). - No explicit announcement of new debt or equity issuance beyond what was used to finance Clario. - The focus is on managing existing capital and leveraging acquisitions opportunistically rather than raising new funds.

- Completed acquisition of Clario in late March, enhancing digital endpoint data solutions and clinical research capabilities. - Strategic collaboration with NVIDIA to commercialize AI-enhanced workflow solutions for scientific instrumentation. - Collaboration with SHL Medical to strengthen U.S. sterile fill-finish and device assembly capabilities using the newly acquired Ridgefield, NJ Sterile fill-finish site. - Opened new Cryo-EM Drug Discovery Center in San Francisco to enhance drug development through Cryo-EM technologies. - Integration progressing smoothly for filtration and separation business acquired from Solventum, driving growth. - Ongoing investments in AI deployment at scale and accelerating cost productivity as part of PPI Business System. - Focus on mitigating tariffs and managing inflationary pressures through operational discipline and supply chain optimization.

- Full-year 2026 revenue guidance raised to $47.3 billion - $48.1 billion, with 3% to 4% organic growth expected. - Midpoint organic growth slightly above 3%, including a $900 million revenue contribution from Clario acquisition. - Second quarter organic revenue growth guidance around 3%, with Q2 adjusted EPS expected $0.25-$0.30 higher than Q1. - China currently at low single-digit decline; no meaningful growth assumed for 2026 but potential upside if conditions improve. - Pharma and biotech businesses, especially bioproduction and clinical research, expected to continue strong growth and share gains. - Analytical Instruments segment faces muted demand but innovation pipeline and easier comparisons suggest normalized growth ahead. - Reshoring activities anticipated as tailwinds for 2027-2028 bioproduction revenue growth. - Overall, company expects steady improvement in performance through 2026, driven by operational execution, innovation, and strategic acquisitions.

- 2026 full-year adjusted EPS guidance raised to $24.64–$25.12, representing 8% to 10% adjusted EPS growth. - Organic revenue growth guidance remains 3% to 4%, with midpoint slightly above 3%. - Guidance includes a $900 million revenue increase and $0.32 EPS contribution from Clario acquisition. - Adjusted operating margin expansion expected at 70 basis points for the year. - Q2 organic revenue growth anticipated around 3%, with adjusted EPS $0.25 to $0.30 higher than Q1. - Strong operational performance and productivity gains projected to continue offsetting inflation and mix challenges. - Confidence expressed in steady market conditions and strategic investments supporting growth. - Free cash flow expected between $6.9 billion and $7.4 billion for 2026.

- The clinical research business demonstrated strong growth in both revenue and authorizations, indicating a robust current order book and pipeline. - There is a "very strong pipeline" of authorizations, referring to work currently underway but not yet in the decision phase, which has moved positively. - The company is seeing continued share gain momentum in clinical research, supported by improving biotech funding. - Early feedback on the recent Clario acquisition is very positive, with customers showing excitement about its technology, suggesting a promising future order pipeline. - The increased authorizations growth and strong pipeline reflect solid demand and ongoing customer reinvestment, especially in early-stage clinical research and R&D. - Overall, both current orders and pending authorizations in clinical research and pharma services are progressing well, supporting optimistic growth expectations.